Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01609569|
Recruitment Status : Unknown
Verified February 2013 by Habib Habib, MD, Saint Michael's Medical Center.
Recruitment status was: Active, not recruiting
First Posted : June 1, 2012
Last Update Posted : February 22, 2013
|Condition or disease|
Pro-calcitonin is a type of protein found in the blood. This protein has recently be found to be elevated in patients with diseases of the arteries of the heart such as heart attack.
Percutaneous coronary intervention (PCI) is widely used in the treatment of many patients with blockage in the arteries of the heart.
the investigators normally used a marker called troponin after cardiac catheterization. However, this marker may not be specific.
Pro-calcitonin has been found to be a useful marker for the detection of myocardial injury. the value of Pro-calcitonin as a marker for the identification of myocardial damage undergoing PCI has not yet been studied.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Utility of Pro-calcitonin as an Indicator of Ischemia in Patients Undergoing Percutaneous Coronary Intervention With Subsequent Coronary Complications.|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||April 2014|
|Estimated Study Completion Date :||May 2014|
patients with coronary complication and patients without coronary complications.
pro-calcitonin will be measured in both groups to see if any correlation.
- Pro-calcitonin blood level [ Time Frame: "0,24 hours post cardiac intervention" ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01609569
|United States, New Jersey|
|Saint Michael's Medical Center|
|Newark, New Jersey, United States, 07102|
|Principal Investigator:||Habib Habib, MD||Saint Michael's Medical Center|
|Study Director:||Fayez Shamoon, MD,FACC||Saint Michael's Medical Center|
|Study Chair:||yaser elnhar, MD||Saint Michael's Medical Center|
|Study Chair:||Vincent Debari, PhD||Saint Michael's Medical Center|
|Study Chair:||Ashraf Jmeian, MD||Saint Michael's Medical Center|
|Study Chair:||Ahmad Isbitan, MD||Saint Michael's Medical Center|